Unknown

Dataset Information

0

Antinuclear Antibodies in Patients with Psoriatic Arthritis Treated or Not with Biologics.


ABSTRACT: With the emergence of biotherapies, accurate diagnosis in early arthritis is needed. At this time, there is no biological marker of psoriatic arthritis.To test whether antinuclear antibodies (ANA) can be used as a diagnostic tool in psoriatic arthritis (PsA), we evaluated the prevalence of ANA in biologic-naïve PsA patients and in healthy blood donors.232 patients from the Rheumatology department, St Marguerite's Hospital, Marseilles, who fulfilled the CASPAR criteria for PsA, underwent clinical and laboratory investigations. Antinuclear antibodies (ANA), anti-extractable nuclear antigen antibodies (ENA), rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA) were assayed. Ninety-one healthy blood donors were also tested.Detection of ANA by indirect immunofluorescence was significantly more frequent in sera from PsA patients than those from controls at serum dilution of 1:100 (57% compared with 40%, Odds Ratio (OR) 1.98 (1.2-3.4) p<0.02) and 1:160 (52% compared with 24%, OR 3,7 (1.9-7.2) p<0.001). No patients had lupus specific autoantibodies, 15 % had RF (34/232), and 1.7 % had ACPA (4/232).Detection of ANA was more frequent in sera from PsA patients than in those from healthy controls. This suggests that ANA could be a diagnosis orientation tool in PsA. Nevertheless, the specificity of these antibodies still remains to be investigated.

SUBMITTER: Silvy F 

PROVIDER: S-EPMC4521886 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Antinuclear Antibodies in Patients with Psoriatic Arthritis Treated or Not with Biologics.

Silvy Florent F   Bertin Daniel D   Bardin Nathalie N   Auger Isabelle I   Guzian Marie-Caroline MC   Mattei Jean-Pierre JP   Guis Sandrine S   Roudier Jean J   Balandraud Nathalie N  

PloS one 20150731 7


<h4>Background</h4>With the emergence of biotherapies, accurate diagnosis in early arthritis is needed. At this time, there is no biological marker of psoriatic arthritis.<h4>Objective</h4>To test whether antinuclear antibodies (ANA) can be used as a diagnostic tool in psoriatic arthritis (PsA), we evaluated the prevalence of ANA in biologic-naïve PsA patients and in healthy blood donors.<h4>Methods</h4>232 patients from the Rheumatology department, St Marguerite's Hospital, Marseilles, who fulf  ...[more]

Similar Datasets

| S-EPMC6882230 | biostudies-literature
| S-EPMC7892371 | biostudies-literature
| S-EPMC5474286 | biostudies-other
| S-EPMC7018889 | biostudies-literature
| S-EPMC5529629 | biostudies-other
| S-EPMC4473767 | biostudies-literature
| S-EPMC3978758 | biostudies-literature
| S-EPMC4883267 | biostudies-literature
| S-EPMC6989349 | biostudies-literature
| S-EPMC8380607 | biostudies-literature